Bevacizumab in the treatment of ovarian cancer
KCE Reports 285 (2017)
Bevacizumab (Avastin®) is a drug used in combination with chemotherapy in ovarian cancer. It keeps the tumor under control for longer, but because of its serious side effects, it decreases the overall quality of life (short-term) of most patients … without it being possible to prove that it increases their total survival. Only patients whose cancer is metastasized outside the abdominal cavity seem to gain significant benefits, with a more favorable cost-effectiveness ratio. These are elements which we consider important to take into account when deciding whether or not to grant a definitive reimbursement for this indication (it is currently the subject of a temporary reimbursement agreement Article 81 in the specific context of ovarian cancer).
How to refer to this report